Cancer Chemotherapy and Pharmacology

, Volume 83, Issue 5, pp 859–866 | Cite as

SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS

  • Ian Joseph CohenEmail author
  • Helen Toledano
  • Jerry Stein
  • Yehuda Kollender
  • Eyal Fenig
  • Osnat Konen
  • Zvi Bar-Sever
  • Josephine Issakov
  • Meora Feinmesser
  • Smadar Avigad
  • Shifra Ash
Original Article



We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94.


Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 courses of chemotherapy, split radiation, and limb salvage surgery. This SCMCIE94 protocol had been used in almost all the patients described in an earlier report, in whom those with non-pelvic isolated tumors and low/absent CD56 expression in Ewing sarcoma tumor cells were all long-term survivors.


The 5-year (10-year) event-free survival rate for the patients with isolated limb primary Ewing sarcoma was 78.95 ± 8.3% (68.6 ± 10.0%) and the overall survival rate was 90.7 ± 6.2% (71.1 ± 11.2%). There were no relapses before 30 months in any of these patients.


The intensified SCMCIE94 pilot protocol has been shown previously to cure patients with localized CD56-negative non-pelvic Ewing sarcoma. The present study shows that among all patients with localized extremity disease who were treated with this protocol, there were no cases of early relapse. Although our cohort was small, the difference in results from studies using other protocols is so striking, that it would seem reasonable to assume it is attributable to the changes made in the protocol itself rather than risk factors. Late relapses of isolated limb CD56-positive Ewing sarcoma suggest minimal residual disease warranting additional therapeutic approaches such as autologous stem cell rescue after Busulfan Melfelan.


SCMCIE94 Non-metastatic Non-pelvic Limb Ewing sarcoma Treatment outcome CD56 Early relapse prevention 



No funding was procured for this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

The study was performed in accordance with the ethical standards established in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board of our center.


  1. 1.
    Jaffe N, Paed D, Traggis D, Salian S, Cassady JR (1976) Improved outlook for Ewing’s sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. Cancer 38:1925–1930CrossRefGoogle Scholar
  2. 2.
    Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664–1674CrossRefGoogle Scholar
  3. 3.
    Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al (2003) Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694–701CrossRefGoogle Scholar
  4. 4.
    Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046CrossRefGoogle Scholar
  5. 5.
    Ash S, Yaniv I, Toledano H, Stein J, Kollender Y, Fenig E et al (2018) Improved outcome in local Ewing Sarcoma with an intensified pilot treatment protocol SCMCIE94. J Ped Hematol Oncol 2018 (in press) Google Scholar
  6. 6.
    Ash S, Luria D, Cohen IJ, Goshen Y, Toledano H, Issakov J al (2011) Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin Cancer Res 17:2900–2907CrossRefGoogle Scholar
  7. 7.
    Dixon WJ (1993) BMDP statistical software. University of California Press, Los AngelesGoogle Scholar
  8. 8.
    Rosen G, Caparros B, Hurvos AG et al (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of post operative chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 110:49;1221–1230Google Scholar
  9. 9.
    Abdul-Karim FW, Buaer TW, Kilpatrick SC, Raymond KA, Siegal GP,. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE et al (2012) Recommendations for the reporting of bone tumors. Hum Path (2004)35; 1173-1178.9. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–4154CrossRefGoogle Scholar
  10. 10.
    Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M et al (2009) Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 27:2536–2541CrossRefGoogle Scholar
  11. 11.
    Ahmed SA, Randall RL, Dubois SG, Harmsen WS, Krailo M, Marcus KJ et al (2017) Identification of patients with localized ewing sarcoma at higher risk for local failure: a report from the childrens oncology group. Int J Radiat Oncol Biol Phys 99:1286–1294CrossRefGoogle Scholar
  12. 12.
    Rosen G, Caparros B, Nirenbirg A, Marcove RC, Huvos AG, Kosloff C, Lane J, Murphy ML (1981) Ewing sarcoma: ten year experience with adjuvant chemotherapy. Cancer 46:2204–2213CrossRefGoogle Scholar
  13. 13.
    Whelan J, Hackshaw A, McTienan A, Grimer R, Spooner D, Bate J et al (2008) Survival is influence by approaches to local treatmrent of Ewing sarcoma within an international randomised controlled trial:analysis of EICESS-92. Clin Sarcoma Res 8:6. CrossRefGoogle Scholar
  14. 14.
    Krasin MJ, Rodriguez-Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, Kun LE (2004) Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 60:830–838CrossRefGoogle Scholar
  15. 15.
    Brown DC, Purushotham AD, Birnie GD, George WD (1995) Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery 1:96–101CrossRefGoogle Scholar
  16. 16.
    Elomaa I, Blomqvist CP, Saeter G, Akerman M, Stenwig E, Wiebe T, Björk O, Alvegård TA (2000) Five-year results in Ewing’s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 36:875–880CrossRefGoogle Scholar
  17. 17.
    Imran H, Enders E, Krailo M, Sim F, Okuno S, Hawkins D et al (2009) Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Jt Surg Am 91:604–612CrossRefGoogle Scholar
  18. 18.
    Cohen IJ, Loven D, Shoenfeld T, Sandbank J, Kaplinsky C, Yaniv Y, Jaber L, Zaizov R (1991) Dactinomycin potentiation of radiation pneumonitis: a forgotten interaction. Ped Hematol Oncol 8:187–192CrossRefGoogle Scholar
  19. 19.
    D’Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V et al (1981) The treatment of Wilms’ tumor: results of the Second National Wilms’ Tumor study. Cancer 47:2302–2311CrossRefGoogle Scholar
  20. 20.
    Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low grade glioma of childhood. J Clin Oncol 11:850–856CrossRefGoogle Scholar
  21. 21.
    Lipshultz S, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153CrossRefGoogle Scholar
  22. 22.
    Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS et al (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol 25:493–500CrossRefGoogle Scholar
  23. 23.
    Cvetković RS, Scott LJ (2006) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005–1024CrossRefGoogle Scholar
  24. 24.
    Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS et al (2017) Treatment pathways of bone sarcoma in children, adolescents, and young adults. Cancer 123:2206–2218CrossRefGoogle Scholar
  25. 25.
    Reichardt P, Tabone M, Mora J et al. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity:re-evaluating the European labeling. Future Oncol.
  26. 26.
    Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD,et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana Farber 91 – 01 acute lymphoblastic leukemia protocol. J Clin Oncol 20:1677–1682CrossRefGoogle Scholar
  27. 27.
    Patel SR, Yadhan-Raj S, Papadopolous N, Plager C, Burgess A, Hayes C et al (1997) High dose ifosfamide in bone and soft tissue sarcomas: results of phase II and piolot studies-dose response and schedule dependence. J Clin Oncol 15:2378–2384CrossRefGoogle Scholar
  28. 28.
    Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K et al (2007) Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110:1568–1577CrossRefGoogle Scholar
  29. 29.
    EURO-E.W.I.N G. Study Committee (1999) EURO-E.W.I.N.G. 99 Study Manual—EUROpean Ewing Tumor Initiative of National Groups Ewing Tumor Studies 1999. Accessed 22 February 2006
  30. 30.
    Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J et al, Children’s Oncology Group (2008) Prognostic factors for patients with Ewing Sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children’s Oncology group. Blood Cancer 51:334–338CrossRefGoogle Scholar
  31. 31.
    Barker LA, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing’s Sarcoma Family of tumors. J Clin Oncol 23:4354–4362CrossRefGoogle Scholar
  32. 32.
    Whelan J, Le Delay MC, Dirksen U, Le Teuff G, Brennan B, Gaspar N et al (2018) High-dose chemotherapy and blood autologous stem -cell rescue compared with standard chemotherapy in localized high-risk Ewing Sarcoma: results of euro-E.W.I.N.G99 and Ewing—2008. J Clin Oncol 36:31103119Google Scholar
  33. 33.
    Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA et al (1999) Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 17:180–190CrossRefGoogle Scholar
  34. 34.
    Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, Bacchini P, Forni C, Manfrini M, Donati D, Picci P (2000) Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 18:4–11CrossRefGoogle Scholar
  35. 35.
    Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Heley JH, LaQualglia MP et al (2003) Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 21:3423–3430CrossRefGoogle Scholar
  36. 36.
    Swartz C, Constine LS, London WB, Sposto R, Friedman DL, Tebbi CK et al (2007) Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkins disease: a claim without evidence In reply. J Clin Oncol 25:4690–4691CrossRefGoogle Scholar
  37. 37.
    Silber JH, Kaixer H (1988) Marginal analysis applied to the dose-response curve. Med Pediatr Oncol 16:344–348CrossRefGoogle Scholar
  38. 38.
    Patel SR, Vadhan-Raj S, Papadopolous N, Plager MA, Burgess A, Hays S, Benjamin RS (1997) High dose Ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies—dose-response and schedule dependence. J Clin Oncol 15:2378–2384CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Ian Joseph Cohen
    • 1
    • 2
    Email author
  • Helen Toledano
    • 1
    • 2
  • Jerry Stein
    • 1
    • 2
  • Yehuda Kollender
    • 2
    • 3
  • Eyal Fenig
    • 2
    • 4
  • Osnat Konen
    • 2
    • 5
  • Zvi Bar-Sever
    • 2
    • 6
  • Josephine Issakov
    • 2
    • 7
  • Meora Feinmesser
    • 2
    • 8
  • Smadar Avigad
    • 2
    • 9
  • Shifra Ash
    • 1
    • 2
  1. 1.The Rina Zaizov Hematology-Oncology DivisionSchneider Children’s Medical Center of IsraelPetach TikvaIsrael
  2. 2.Sackler faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Unit of Orthopedic OncologyTel Aviv Medical CenterTel AvivIsrael
  4. 4.Department of Radiotherapy, Rabin Medical CenterBeilinson HospitalPetach TikvaIsrael
  5. 5.Department of Pediatric RadiologySchneider Children’s Medical Center of IsraelPetach TikvaIsrael
  6. 6.Department of Nuclear MedicineSchneider Children’s Medical Center of IsraelPetach TikvaIsrael
  7. 7.Institute of PathologySourasky Tel Aviv Medical CenterTel AvivIsrael
  8. 8.Institute of PathologyBeilinson HospitalPetach TikvaIsrael
  9. 9.Molecular Oncology, Felsenstein Medical Research CenterBeilinson HospitalPetach TikvaIsrael

Personalised recommendations